Lobivir ®



<u>Lobivir</u>

Each film-coated tablet contains Composition

Lamivudine100 mg

Indications

Lobivir HBV is indicated for the treatment of chronic Hepatitis B and evidence of hepatitis B virus (HBV) replication in patients with decompensated liver disease or active inflammation and/or fibrosis.

Description

Lamivudine (ß-L-2',3'-dideoxy-3'-thiacytidine), one of the dideoxycytidine (ddC) analogue NRTIs, is the first nucleoside analogue approved to treat chronic HBV infection and has been shown to benefit various categories of patients. These include HBe-positive and -negative patients, non-responders to interferon-{alpha} therapy, and patients with decompensated cirrhosis.

Lamivudine's D-isomer is less active against HBV replication and more cytotoxic than the Lisomer. Both the D- and L-isomers of 2',3'-dideoxy- 3'-thiauridine were found to be inactive against HBV replication, and the susceptibility of the thiacytidine stereoisomers to cytidine and/or deoxycytidine deaminase was suspected to be the reason. In fact, the racemic mixture and the Disomer of 2',3'-dideoxy-3'-thiacytidine were deaminated with partially purified human deaminase and were found to be processed to the

D-isomer of the thiauridine, while lamivudine and ddC were not. Despite the intracellular stability of its cytosine base, ddC was less effective than lamivudine in a cell culture system. Until recently, it was thought that the potency of lamivudine reflected the higher incorporation efficiency into newly synthesized DNA by the viral DNA polymerase. Lamivudine and ddC are phosphorylated to their triphosphates and then the triphosphates act as chain terminators during viral and cellular DNA synthesis.

CONTRA-INDICATIONS

EPIVIR Tablets and Oral Solution are contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of the products.

<u>Dosage</u>

The recommended dosage of Lobivir HBV is 100 mg once daily or as per the physician's advice.

Presentations

10 tablets

Taj Group Pharmaceuticals

Taj Pharmaceuticals Limited, Taj Group Pharmaceuticals Division Andheri (w), Maharashtra 4000 53, INDIA Revised Every Year 6794553d Www.tajfordoctors.com